#United States #Chicago #oncology #ASCO 2025 #Canopy

Canopy's Advancements in Oncology Monitoring at ASCO 2025

At the upcoming American Society of Clinical Oncology (ASCO) annual meeting, Canopy is set to unveil exciting new findings from two pivotal studies that leverage its groundbreaking Remote Therapeutic Monitoring (RTM) Platform. Designed specifically for oncology, this platform aims to transform how treatment experiences are captured and understood by utilizing Electronic Health Records (EHR) integrated tools.

Unveiling Real-World Insights

The studies focus on patients undergoing various treatments for melanoma and breast cancer, revealing how regimen-specific symptoms can be effectively monitored and analyzed. The first presentation will showcase the insights gained from the Electronic Patient-Reported Outcomes (ePRO) system, which garnered significant attention for its innovative approach to assess treatment responses among patients receiving immune checkpoint inhibitors like pembrolizumab and nivolumab.

The study, titled Insights from the Canopy ePRO System, will take place on Saturday, May 31. Researchers found that patients on pembro reported significantly lower incidence of symptoms compared to those on other regimens. The findings not only highlight the variations in side effects experienced by patients but also the need for personalized monitoring, allowing clinicians to intervene more proactively based on real-time symptom reports. Benjamin Derman, MD, an Assistant Professor of Medicine at the University of Chicago and the study's lead author, emphasized, "This study underscores that the effects of immune checkpoint inhibitors can differ markedly across patients."

Insights from Breast Cancer Treatment

The second study, focusing on breast cancer patients undergoing adjuvant chemotherapy, further demonstrates the versatility of the RTM platform. Analyzing symptom trends for patients treated with either doxorubicin/cyclophosphamide (ACT) or docetaxel/cyclophosphamide (TC) regimens, this research highlights how symptom experiences can vary even among treatments considered clinically equivalent. The study captures critical insights into common side effects to aid clinicians in providing tailored supportive care.

Michael Kolodziej, MD, Canopy’s Chief Medical Officer and lead author of this study, stated, "ePROs provide indispensable insights into patient experiences that can address the nuances of each regimen. Understanding these differences can greatly enhance decision-making processes in clinical practice."

Previous Research Highlights

Canopy has previously demonstrated the efficacy of its platform through compelling research outcomes, showcasing:

• - A 45% increase in treatment persistence over three months.
• - A 22% decrease in emergency room visits and hospitalizations.
• - Sustained patient engagement, with 88% remaining active six months into treatment.

Commitment to Transforming Oncology Care

Canopy's Continuous Care Platform is designed for oncology practices across the United States, supporting a growing network of over 2,000 providers. Their mission is to enhance patient care through comprehensive monitoring solutions that identify needs between visits. By integrating advanced AI tools, Canopy not only resolves issues efficiently but also opens new avenues for reimbursement, reflecting its commitment to improving oncology patient outcomes.

With their presentations at ASCO 2025, Canopy aims to not only highlight its technological advancements but also shape the future of oncology care by differentiating symptoms as experienced by patients in real-world settings.

To learn more about Canopy's innovative approach and their ongoing research, visit Canopy's website.